IMMUTOL: Advanced antigen-specific dendritic cell-based therapy to re-establish tolerance in immunemediated diseases
Investigador principal
Grupo de investigación
Fuente de financiación:
Unión Europea
Periodo:
01/05/2023 a 30/04/2027
Tipología del proyecto:
Proyecto Consorcio Europeo
Estado del proyecto:
ACTIVO
Entidad financiadora:
Comisión Europea (CE)
Financiación:
273.778.75 €
IMMUTOL is the Accelerated development and validation of an advanced therapeutic drug (ATMP) based on modified VitD3
The aim of IMMUTOL isthe fast-track development and validation of an advanced therapeutic medicinal product (ATMP) based on VitD3-modified tolerogenic DC for immunotherapy approaches.
Through a multidisciplinary approach, IMMUTOL will leverage the power of tolerogenic VitD3DC-based immunotherapy to develop a more potent and durable treatment for MS and, in turn other autoimmune inflammatory diseases with an unmet medical need. In parallel, it will bring information about tolerance mechanisms and patient-specific requirements for manufacturing effective tolDC products.https://immutol-horizon.eu
Colaboradores
Fondazione Telethon ETS
Ospedale San Raffaele SRL
Institut de Investigació en Ciències de la Salut Germans Trias i Pujol
Stichting Sanquin Bloedvoorziening
Universidad de Navarra
Asphalion SL
Syreon Kutato Intezet Korlatolt Felelossegu Tarsasag
Innovation Acta SRL
Asociación de Esclerosis Múltiple de Toledo
Noticias relacionadas
